Caisse de depot et placement du Quebec Purchases New Position in Medpace Holdings, Inc. $MEDP

Caisse de depot et placement du Quebec purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 152,908 shares of the company’s stock, valued at approximately $80,979,000. Caisse de depot et placement du Quebec owned about 0.55% of Medpace at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of MEDP. Odyssean LLC purchased a new position in shares of Medpace during the second quarter valued at approximately $3,369,000. Man Group plc purchased a new position in Medpace during the 2nd quarter valued at $11,082,000. Roberts Glore & Co. Inc. IL purchased a new position in Medpace during the 2nd quarter valued at $2,039,000. Polar Asset Management Partners Inc. bought a new position in Medpace in the 2nd quarter worth $236,000. Finally, Jupiter Topco LLC bought a new position in Medpace in the 2nd quarter worth $69,402,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MEDP shares. Royal Bank Of Canada lifted their target price on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Truist Financial increased their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Mizuho lifted their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Price Performance

Shares of Medpace stock opened at $611.57 on Friday. The company has a 50-day moving average of $562.52 and a 200 day moving average of $493.80. The firm has a market cap of $17.07 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling

In related news, CFO Kevin M. Brady sold 3,400 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total value of $2,125,816.00. Following the sale, the chief financial officer owned 12,830 shares in the company, valued at $8,021,829.20. This represents a 20.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 129,963 shares of company stock valued at $79,364,624. 20.50% of the stock is owned by company insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.